Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23116411 | 0.97 | ROCK2 (0.48) | ROCK2GPBAR1SCD5HCRTR1HCRTR2 | |
| SCHEMBL23116377 | 0.89 | HSD17B10 (0.48) | ROCK2SCD5HCRTR1HCRTR2HSD17B10 | |
| SCHEMBL22729509 | 0.87 | HSP90AA1 (0.46) | ROCK2GPBAR1SCD5 | |
| SCHEMBL22754965 | 0.86 | HSD17B10 (0.51) | ROCK2SCD5HCRTR1HCRTR2HSD17B10 | |
| SCHEMBL22729499 | 0.84 | HSP90AA1 (0.49) | SCD5 | |
| SCHEMBL22729681 | 0.82 | RIPK1 (0.42) | ROCK2SCD5HCRTR1HCRTR2 | |
| SCHEMBL29839310 | 0.82 | RIPK1 (0.42) | ROCK2SCD5HCRTR1HCRTR2 | |
| SCHEMBL23116410 | 0.82 | HSP90AA1 (0.52) | ROCK2GPBAR1SCD5HCRTR1HCRTR2 | |
| SCHEMBL22729659 | 0.81 | ROCK2 (0.39) | ROCK2SCD5HCRTR1HCRTR2HSD17B10 | |
| SCHEMBL22729502 | 0.80 | RIPK1 (0.47) | SCD5HCRTR1HCRTR2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | ROCK2 1789/4885GPBAR1 1959/4885SCD5 1293/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | ROCK2 1789/4885GPBAR1 2000/4885SCD5 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.